1-6 of 6
Nehal Lakhani, MD, PhD
Close
Sort by
Journal Articles

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Alison J. Forgie, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MDPhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-135941
Published: 2020
Journal Articles

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MD PhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1953.
https://doi.org/10.1182/blood-2019-123219
Published: 2019
Journal Articles

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

Wael A Harb, MD, Catherine S Diefenbach, MD, Nehal Lakhani, MD PhD, Sarah C Rutherford, MD, Marshall T Schreeder, MD, Stephen M Ansell, MD PhD, Taimur Sher, MD, David M Aboulafia, MD, Jonathon B Cohen, MDMS, Darrell Nix, BS, PhD, Sean Landrette, PhD, Kate Flanders, BS, Langdon L Miller, MD, Henri Lichenstein, PhD, Jeremy S. Abramson, MD MMSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 4119.
https://doi.org/10.1182/blood.V130.Suppl_1.4119.4119
Published: 2017
Journal Articles

Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies

Max S. Topp, MD, Peter Borchmann, MD, Nina D. Wagner-Johnston, MD, Mariano Provencio, MD, Raul Cordoba, MDPhD, Kyriakos Papadopoulos, MD, Alejandro Martín, MD PhD, Carlos Grande, MD, Deepa Jagadeesh, MDMPH, Nehal Lakhani, MD PhD, Sven de Vos, MD PhD, Anthony R. Mato, MD, Uta Brunnberg, MD, Sebastian Scholl, MD, Christiane Pott, MD, PhD, Sarah C Rutherford, MD, Johannes Duell, MD, Lieve Adriaens, PharmD, Melanie Ufkin, BS, PhD, Ana Kostic, PhD, Anne Josee Paccaly, PharmD, PhD, Bo Gao, PhD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Cecilia Carpio, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1495.
https://doi.org/10.1182/blood.V130.Suppl_1.1495.1495
Published: 2017
Journal Articles

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Wael A. Harb, MD, Nehal Lakhani, MD PhD, Ana Logsdon, LPN, Clinical Research Coordinator, Mary Steigelman, RN, Heidi Smith-Green, BSN, RN, Shari Gaylor, RN, Wendi Rodrigueza, PhD, Michael Woolliscroft, BA, MBA, Mina Sooch, BS, MBA, Richard A. Messmann, MD MHS, MSc, Ayad Al-Katib, MD FACP
Journal: Blood
Blood (2014) 124 (21): 1716.
https://doi.org/10.1182/blood.V124.21.1716.1716
Published: 2014
Journal Articles

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma

Wael A. Harb, MD, Nehal Lakhani, MD, PhD, Ana Logsdon, LPN, Clinical Research Coordinator, Mary Steigelman, RN, Heidi Smith-Green, BSN, RN, Shari Gaylor, RN, Michael Woolliscroft, BA, MBA, Wendi Rodrigueza, Ph.D., Mina Sooch, BS, MBA, Richard A. Messmann, MD, MHS, MSc, Ayad Al-Katib, MD, FACP
Journal: Blood
Blood (2013) 122 (21): 88.
https://doi.org/10.1182/blood.V122.21.88.88
Published: 2013